Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

BACKGROUND AND OBJECTIVES: Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). Study AB07002 assessed oral masitinib in patients with progressive MS who were prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermersch, Patrick, Brieva-Ruiz, Luis, Fox, Robert J., Paul, Friedemann, Ramio-Torrenta, Lluis, Schwab, Matthias, Moussy, Alain, Mansfield, Colin, Hermine, Olivier, Maciejowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005047/
https://www.ncbi.nlm.nih.gov/pubmed/35190477
http://dx.doi.org/10.1212/NXI.0000000000001148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005047/
https://www.ncbi.nlm.nih.gov/pubmed/35190477
http://dx.doi.org/10.1212/NXI.0000000000001148

Ejemplares similares